longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

CURALEAF HOLDINGS INC

CURLD

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -60.50, within the reasonable range, cheaper than 90.28% of the time in the past 1 years, and the industry ranks 222/257, the industry Median -1.31.

-60.5xP/E
--Stock price
-60.5xP/E
Stock price--

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-60.50x
Typical range
-60.50x–-60.50x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
TAKUSTakeda Pharmaceutical Company
-56.58x14.01%$59.08B
BAYZFUSBayer Aktiengesellschaft
-27.97x--$56.43B
BAYRYUSBayer
-27.34x--$55.15B
VTRSUSViatris
-46.56x110.35%$19.12B
VREOFUSVIREO GROWTH INC
-175.07x--$11.75B
ELANUSElanco Animal Health
-57.75x129.36%$11.49B
AXSMUSAxsome Therap
-55.78x27.32%$10.69B
CURLFUSCuraleaf Holdings, Inc.
-148.89x--$7.75B
BLTEUSBelite Bio
-66.66x29.87%$6.82B
DFTXUSDefinium Therapeutics
-13.98x53.32%$4.95B
EWTXUSEdgewise Therapeutics
-24.03x137.29%$4.74B
MANEUSVeraDermics
-41.62x97.39%$4.34B
AMLXUSAmylyx Pharmaceuticals
-27.36x1.76%$4.16B
ELVNUSEnliven Therapeutics
-36.91x1.17%$3.91B
TARSUSTarsus Pharmaceuticals
-73.87x34.09%$3.43B
MBXUSMBX Biosciences
-28.21x30.54%$2.94B
GPCRUSStructure Therapeutics
-12.93x104.48%$2.78B
RGCUSRegencell Bioscience
-393.65x--$2.77B
PHVSUSPharvaris BV
-13.47x7.70%$2.67B
SUPNUSSupernus Pharma
-21.84x70.59%$2.40B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.